植物提取物对心力衰竭患者的影响:随机对照试验的网络元分析
Jieyin Deng1, Ye Huang2, Dehui Fu1
1Department of General Medical Practice, The General Hospital of Western Theater Command, Chengdu, China.
Frontiers in pharmacology
|November 21, 2025
概括
这次审查发现,包括阿斯特拉加勒斯和沈在内的几种植物提取物在改善心力衰竭症状和心脏功能方面表现有前途. 需要进一步的高质量试验来证实这些对心力衰竭管理的好处.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 综合医学是一个整体的医学.
背景情况:
- 心力衰竭 (HF) 是一个重要的全球健康负担,传统治疗的局限性.
- 植物提取物由于其药用特性和较少的副作用,为HF提供了潜在的治疗益处.
研究的目的:
- 系统地审查和网络分析各种植物提取物在治疗心力衰竭 (HF) 的有效性.
- 为HF患者选择最佳植物性疗法提供基于证据的指导.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane图书馆) 进行了系统的文献搜索.
- 包括的研究被选,提取数据,并评估质量.
- 网络元分析 (NMA) 用于比较多种植物提取物对HF结果的直接和间接影响.
主要成果:
- 分析了20项涉及2077名患者的研究.
- 阿斯特拉加卢斯提取物在改善6分钟步行测试 (6-MWT) 和减少瘤亡因子-α (TNF-α) 中显示出最高的疗效.
- 沈提取物在降低B型尿素 (BNP) 和提高生活质量 (QL) 中表现出色;红人参改善左心室喷射率 (LVEF);金刚果改善了纽约心脏协会 (NYHA) 的分类.
结论:
- 特定的植物提取物,如,沈,红人参,银杏花和Terminalia arjuna在控制心力衰竭指标方面表现出显著的有效性.
- 进一步的大规模,高质量的随机对照试验 (RCT) 对于验证这些发现和优化植物提取物在HF治疗中的使用至关重要.
更多相关视频
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
1.3K
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.7K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
01:30Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
01:22Heart Failure Drugs: β-Blockers
741
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
741
01:22Heart Failure Drugs: Diuretics
775
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
775
01:22Heart Failure VI: Adjunct Therapies
239
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
239
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K